B of A Securities Downgrades Ambev to Underperform, Maintains Price Target to $3.3
B of A Securities analyst Isabella Simonato downgrades Ambev (NYSE:ABEV) from Neutral to Underperform and maintains the price target from $3.3 to $3.3.
Stocks · News reference
This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Analysts downgraded PJT, OPCH, CRBU, ABEV , cutting price targets for PJT, CRBU.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of U.S.-traded companies with Brazil exposure are trading higher after the first round of Presidential election balloting showed right-wing candidate Flavio Bolsonaro with a lead over Lula, the current left-wing President. The results may indicate a possible pro-business final election outcome ahead of the October 25 run-off vote, wherein the winning candidate must achieve a majority above 50%.
RXO, Vaxcyte, PTC And Other Big Stocks Moving Higher On Monday
U.S. stocks mixed as Dow falls 250+ points; RXO surges 23% on $5.8B C.H. Robinson deal, while Vaxcyte and PTC post major gains.
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
Brookline Capital Downgrades Caribou Biosciences to Hold
Brookline Capital analyst Leah Cann downgrades Caribou Biosciences (NASDAQ:CRBU) from Buy to Hold.
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.